Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOKSLUTSKOMMUNIKÉ 2017 FJÄRDE KVARTALET - OKTOBER - DECEMBER 2017 Nettoomsättningen uppgick till 0,4 (0,0) KSEK Kostnaderna uppgick till 2,5 (2,1) MSEK Resultatet före och efter skatt...
-
The scientific results from intratumoral injections with Liproca® Depot as confirmed by Magnetic Resonance Imaging and Spectroscopy, have been accepted for presentation at the International Society...
-
LIDDS AB (publ) board has decided on a direct share issue to Nyenburgh Holding, a Dutch Life Science Fund that invests in selected European biotech- and pharma companies. The raised capital will...
-
LIDDS has successfully completed another preclinical study in mice assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy. Clear anti-tumor effects...
-
LIDDS has successfully completed the first steps in one of its projects assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy with positive...
-
An external analysis concludes that a five years patent extension is expected in Europe and predicts a similar extension procedure in the US provided that the pharmaceutical substances in NanoZolid...
-
LIDDS has started four internal projects that focus on assessing the feasibility of using the NanoZolid® drug delivery technology for local or intratumoral immunotherapy. These feasibility studies...
-
LIDDS has received approval from the Indian patent office for its patent on "Method for treatment of prostate cancer and other prostate diseases" with the NanoZolid® drug delivery technology...
-
JULI - SEPTEMBER 2017 Nettoomsättningen uppgick till 0,2 (0,0) KSEK Kostnaderna uppgick till 1,5 (1,6) MSEK Resultatet före och efter skatt uppgick till -1,5 (-1,6) MSEK Resultat per aktie...
-
LIDDS has entered a research collaboration with the Department of Laboratory Medicine at Karolinska Institute, Sweden. The collaboration regards fundamental preclinical studies on formulations based...